scholarly journals Eradication of HCV Infection with the Direct-Acting Antiviral Therapy in Renal Allograft Recipients

2019 ◽  
Vol 2019 ◽  
pp. 1-8 ◽  
Author(s):  
Armando Calogero ◽  
Evangelista Sagnelli ◽  
Massimiliano Creta ◽  
Silvia Angeletti ◽  
Gaia Peluso ◽  
...  
Keyword(s):  
Antiviral Agents ◽  
Virologic Response ◽  
Hcv Infection ◽  
Renal Transplant Recipients ◽  
Transplant Recipients ◽  
Direct Acting Antiviral ◽  
Increased Risk ◽  
The Subject ◽  
Direct Acting ◽  
Direct Acting Antiviral Agents

Hepatitis C virus (HCV) infection unfavorably affects the survival of both renal patients undergoing hemodialysis and renal transplant recipients. In this subset of patients, the effectiveness and safety of different combinations of interferon-free direct-acting antiviral agents (DAAs) have been analyzed in several small studies. Despite fragmentary, the available data demonstrate that DAA treatment is safe and effective in eradicating HCV infection, with a sustained virologic response (SVR) rates nearly 95% and without an increased risk of allograft rejection. This review article analyzes the results of most published studies on this topic to favor more in-depth knowledge of the readers on the subject. We suggest, however, perseverating in this update as the optimal DAA regimen may not be proposed yet, because of the expected arrival of newer DAAs and of the lack of data from large multicenter randomized controlled trials.

Case 21

2020 ◽  
pp. 137-142
Author(s):  
Will Irving
Keyword(s):  
Antiviral Agents ◽  
Virologic Response ◽  
Hcv Infection ◽  
Direct Acting Antiviral ◽  
Chronic Hcv Infection ◽  
Chronic Hcv ◽  
Direct Acting ◽  
End Stage ◽  
Hcv Testing ◽  
Direct Acting Antiviral Agents

Chronic hepatitis C (HCV) infection may be completely asymptomatic until the patient presents with complications of end-stage liver disease. Hence, anti-HCV testing should be performed on any patient with risk factors, which includes a raised alanine aminotransferase. Following diagnosis of chronic HCV infection, it is essential to know the genotype of the infecting virus, and whether or not the patient has underlying cirrhosis, as both of these factors will be important in determining the optimal therapeutic regimen. Direct-acting antiviral agents target 3 different viral non-structural proteins. The success of these drugs in achieving sustained virologic response (SVR) in well over 90% of patients in clinical trials has ended the era of interferon-based therapy for this infection. Therapy for most patients comprises one co/multiply-formulated tablet taken orally per day for 8 or 12 weeks.

DI-062 Sustained virologic response rates of new direct acting antiviral agents for HCV

2016 ◽  
Vol 23 (Suppl 1) ◽  
pp. A145.2-A146
Author(s):  
C Caballero Requejo ◽  
M Onteniente Candela ◽  
JJ Franco Miguel ◽  
M Garcia Coronel ◽  
A Trujillano Ruiz ◽  
...  
Keyword(s):  
Sustained Virologic Response ◽  
Antiviral Agents ◽  
Response Rates ◽  
Virologic Response ◽  
Direct Acting Antiviral ◽  
Direct Acting ◽  
Direct Acting Antiviral Agents
Sign in / Sign up

Export Citation Format

Share Document